Cohen S E, Yeh J Y, Riley E T, Vogel T M
Department of Anesthesia, Stanford University School of Medicine, California 94305, USA.
Anesthesiology. 2000 Feb;92(2):387-92. doi: 10.1097/00000542-200002000-00019.
Regional analgesia techniques for labor that permit ambulation are popular among parturients. This study evaluated the influence of bupivacaine bolus concentration and a 3-ml 1.5% lidocaine-epinephrine test dose, on analgesic effectiveness and the ability to walk after block placement.
Using a randomized double-blind study design, epidural analgesia was initiated in 60 parturients undergoing labor as follows: Group TD/B.0625 received a 3-ml lidocaine-epinephrine test dose + 12 ml bupivacaine, 0.0625%; group TD/B.125 received a 3-ml test dose + 12 ml bupivacaine, 0.125%; group B.0625 received 15 ml bupivacaine, 0.0625% (no test dose); and group B.125 received 15 ml bupivacaine, 0.125% (no test dose). Initial boluses in all groups contained 10 microg sufentanil. Bupivacaine, 0.0625%, with 0.33 microg/ml sufentanil was infused throughout labor at 13.5-15 ml/h. Analgesia balance, proprioception, motor block, and patient ability to stand and walk were evaluated at various intervals.
A bolus of 0.125% bupivacaine containing sufentanil, without a previous test dose, proved to be optimal with respect to analgesia and early ambulation. When a test dose was given before bupivacaine, 0.125%, fewer women walked within 1 h of block placement. Bupivacaine, 0.0625%, with sufentanil, with or without a test dose, provided inadequate analgesia, necessitating additional bupivacaine, which impaired the ability to walk. A high percentage of women in all groups (73-93%) walked at some stage during labor.
Omitting a lidocaine-epinephrine test dose and using 0.125% bupivacaine for the initial bolus should permit ambulation in the early postblock period for most parturients who elect this option.
允许产妇行走的分娩区域镇痛技术在产妇中很受欢迎。本研究评估了布比卡因推注浓度和3毫升1.5%利多卡因-肾上腺素试验剂量对镇痛效果及阻滞放置后行走能力的影响。
采用随机双盲研究设计,对60例分娩产妇实施硬膜外镇痛,分组如下:TD/B.0625组接受3毫升利多卡因-肾上腺素试验剂量+12毫升0.0625%布比卡因;TD/B.125组接受3毫升试验剂量+12毫升0.125%布比卡因;B.0625组接受15毫升0.0625%布比卡因(无试验剂量);B.125组接受15毫升0.125%布比卡因(无试验剂量)。所有组的初始推注均含有10微克舒芬太尼。分娩全程以13.5 - 15毫升/小时的速度输注含0.33微克/毫升舒芬太尼的0.0625%布比卡因。在不同时间间隔评估镇痛平衡、本体感觉、运动阻滞以及患者站立和行走的能力。
含舒芬太尼的0.125%布比卡因推注,无前试验剂量,在镇痛和早期行走方面被证明是最佳的。在给予0.125%布比卡因前给予试验剂量时,阻滞放置后1小时内行走的女性较少。含或不含试验剂量的0.0625%布比卡因与舒芬太尼联合使用,镇痛效果不佳,需要额外使用布比卡因,这会损害行走能力。所有组中高比例(73 - 93%)的女性在分娩的某个阶段能够行走。
对于大多数选择该方案的产妇,不使用利多卡因-肾上腺素试验剂量并将0.125%布比卡因用于初始推注应能使其在阻滞放置后的早期实现行走。